The expanding CRISPR-Cas9 technology is an easily accessible, programmable, and precise gene-editing tool with numerous applications, most notably in biomedical research. Together with advancements in genome and transcriptome sequencing in the era of metadata, genomic engineering with CRISPRCas9 meets the developmental requirements of precision medicine, and clinical tests using CRISPR-Cas9 are now possible. This review summarizes developments and established preclinical applications of CRISPR-Cas9 technology, along with its current challenges, and highlights future applications in translational research.
Gene therapy is a form of disease treatment that involves the alteration of DNA or RNA, thereby counteracting or remedying the conditions caused by malfunctioning genes. 1 Although gene therapy remains a risky technique and is being tested, it is undoubtedly a promising treatment option for human diseases, [2] [3] [4] [5] including inherited disorders, some types of cancer, and certain viral infections, because it has the capacity to cure diseases at the roots. 1 Such nucleic acid manipulation techniques must rely on rapid developments in deep genome and transcriptome sequencing platforms that allow precise and comprehensive analysis of disease pathogenesis. Disease treatment is inevitably focused on determining unique molecular characteristics of individual patients, as a subfield of precision medicine. 6 Among the tools available for precision-based gene therapy, CRISPR-Cas9 has revolutionized the field, allowing for simple, timesaving, and cost-efficient eukaryotic genome editing. 7 Since 2013, when this technology was validated in human cells, the RNA-guided CRISPR-Cas9 system has been applied for DNA and RNA manipulation in numerous cell lines and organisms. 8, 9 CRISPR-Cas9 can generate loss-of-function mutations in genes, precise genome-site knockins, site modifications, and transcriptome and epigenome alteration. 10 Considering its expanding repertoire of applications, CRISPR-Cas9 is a promising method for optimizing biomedical research and innovate treatment strategies for gene-associated diseases such as hereditary diseases 11 and malignancies. 12 Thus far, CRISPR-Cas9 has successfully cured genetic diseases in animal models. The first clinical trials involving CRISPR-Cas9 were initiated in 2016 and continue to this day. 13 Excitingly, a recently approved clinical trial (ClinicalTrials.gov: NCT03655678) will use CRISPRCas9-modified therapeutic human hemopoietic stem cells (hHSCs), called CTX001, to treat thalassemia.
Unlike in genetic diseases, one or two causative genes cannot explain cancer pathogenesis. Because of the complex biological characteristics of cancers, the search for an optimal treatment for cancer patients has been an ongoing race. The most promising tumor treatment is immunotherapy, involving the use of immune checkpoint inhibitors and adoptive immune cell therapy. CRISPR-Cas9 technology is able to transfer tumor-specific identification signals into cytotoxic immune cells and remove immune repressor genes of these cells that are retransfused into patients for cancer treatment. The therapeutic potential is being investigated in multiple clinical trials (ClinicalTrials.gov: NCT02793856, NCT03044743, NCT03398967, and NCT03081715). 13 This review summarizes the basic mechanisms and general applications of CRISPR-Cas9 gene editing and discusses technological applications, advancements, and challenges of this exciting technology in preclinical and clinical translational research.
Overview of CRISPR-Cas9 Technology
CRISPR-Cas9 technology was first described as a series of short repeats interspaced with short sequences in the Escherichia coli genome 14 and was officially named in 2002. 15 The technology was functionally verified as adaptive immunity 16 and used to cleave target DNA sequences. 17 Because this technology was initially used to target the human genome in 2013, [18] [19] [20] its applications have increased tremendously in biomedical research (Figure 1 ). Based on effector proteins, CRISPR-Cas systems are grouped into two classes that are further subdivided into six types (I-VI) in accordance with their signature genes (class 1: types I, III, and IV; class 2: types II, V, and VI). 21 Class 2 systems are characterized by single-subunit effector proteins such as Cas9 and Cas12a (Cpf1). These have been more successfully reprogrammed for genome engineering than class 1 systems, although the latter comprise 90% of all CRISPR-Cas systems identified in bacteria and archaea.
Genome engineering using CRISPR-Cas9 is initiated with RNAguided Cas9 endonuclease inducing double-strand breaks (DSBs) adjacent to PAM (a short, Cas9-recognized sequence) in the genome of transformed cells. These breaks then activate DNA repair mechanisms through two possible pathways. Target gene functional knockout occurs upon triggering of the non-homologous end joining (NHEJ) pathway. The second pathway is homology-directed repair (HDR), which introduces a precise genetic knockin through an exogenous template 7, 24 ( Figure 2A ).
Other than these basic manipulations, advancements in CRISPRCas9 technology have resulted in extended complex applications. The system can perform pooled high-throughput genetic screens ( Figure 2F ). 24 In addition, dead Cas9 (dCas9) is a catalytically deactivated Cas9 nuclease ( Figure 2C ) that can be fused with transcription factors, fluorescent marker proteins, and other functional proteins to regulate gene expression, track target genes, and make unexpected genomic alterations. 7 Fusion of a deaminase to dCas9 generated a novel base-editing technology ( Figure 2D) , resulting in precise and highly efficient C-to-T or G-to-A modifications. 25 Moreover, dead guide RNA (dgRNA), with a short 14-to 15-nucleotide (nt) sequence and MS2-binding loops into the backbone, can activate transcription without inducing DSBs ( Figure 2E ). 26 Furthermore, the development of double-nickase Cas9 ( Figure 2B ) expands the translational application of CRISPR-Cas9 through the generation of a staggered single cleavage in the genome, reducing off-target effects. 7 This method minimizes off-target editing and has been used in multiple studies. 7 The following sections describe the most important applications of CRISPR-Cas9 thus far. First, the system generates animal and cellular models of diseases more rapidly and conveniently 28 and provides novel insights into disease treatment. 29 Such methods include rectification of genomic variations in human embryonic cells and stem cells. 30 Second, high-throughput CRISPR can help screen candidates during systematic genetic functional analyses and identify new drug targets. 24, 31 Third, dCas9 is useful for regulating gene expression 32 and for posttranscriptional RNA base editing. 9, 33 Fourth, CRISPR-Cas9 is valuable for nucleic acid-based imaging, detection, and diagnosis. 10 Finally, Figure 3 summarizes the applications of CRISPR-Cas9 technology in agriculture, material science, and various other fields.
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Major Advancements in the Application of CRISPR-Cas9 in Genetic Diseases
In non-human studies, CRISPR-Cas9 is routinely used for genomic and transcriptomic engineering to induce epigenetic effects. 10, 29, 34 While these non-patient experiments provide a fundamental platform for understanding the complex action mode of CRISPR-Cas9 components, we focus on studies that have greater direct clinical translation. Although existing treatments can attenuate the symptoms of some hereditary diseases, patients still suffer from considerable psychological or social pressure for possessing mutation-associated conditions. Although considerable ethical and regulatory issues remain to be addressed, major progress has been made with the use of CRISPR-Cas9 technology to rectify pathogenic gene mutations in human embryos. 47 The CRISPR-Cas9 base editor (BE) has been reported to yield targeting efficiency of 89% in rectifying FBN1 mutations in Marfan syndrome 30 but only 23% in rectifying HBB-28 (A > G) mutations in b-thalassemia. 48 More encouragingly, CRISPR-Cas9 gene editing has successfully helped rectify MYBPC3 mutations associated with hypertrophic cardiomyopathy in human embryos, with a targeting efficiency of 72.2%, and embryos exhibited no mosaicism, no off-target gene editing, and no other abnormalities. 49 Moreover, embryos preferred the gene copies of the healthy parent to that of an exogenous DNA donor as a repair template. Such a preference may reduce ethical concerns to a certain extent, although further studies are required to improve the targeting efficiency and determine the long-term safety of CRISPR-Cas9 technology. A study using CRISPR-Cas9 BE to edit murine pathological Pcsk9 and Hpd genes in utero reported high editing efficiency, tolerance to CRISPR components, and amelioration of murine HT1 at birth even without nitisinone treatment. 50 These studies have strong clinical implications for CRISPR-Cas9 gene editing in human embryos and fetuses.
Significant advancements have been made in using CRISPR-Cas9 to treat other diseases on some genetic basis. For example, transcriptionally activated CRISPR-Cas9 with short dgRNA (14 or 15 bp) successfully alleviated disease phenotypes in mouse models of type 1 diabetes, acute kidney injury, and muscular dystrophy. 51 Similarly, CRISPR-mediated genome editing partially improved symptoms in SOD1-linked forms of amyotrophic lateral sclerosis and autosomal dominant hearing loss. 52, 53 These advancements provide promising insights into the eventual translation of CRISPR gene editing into the clinical setting.
Promising Breakthroughs in Cancer Treatment Using CRISPRCas9 Technology CRISPR-Cas9 genome editing has been considered a powerful tool in cancer research. The technology can be used to investigate tumorigenesis and tumor invasion. 54 Encouraging studies suggest that CRISPRCas9 is valuable for the rapid development of cancer immunotherapy.
Adoptive gene-engineered T cell immunotherapy is one of the most promising cancer treatment strategies, including chimeric antigen receptor (CAR)-and T cell receptor (TCR)-T cell therapy. The former has succeeded in treating hematological malignancies, but not in treating solid tumors. 55 CARs generally comprise an extracellular tumor antigen-recognized domain and an intracellular signal-activating domain. 56 The primary contribution of CRISPR-Cas9 technology is to simplify CARs or TCR gene editing, thus elevating the potency and safety of cancer-adoptive T cell therapy. For example, using CRISPR-Cas9 to direct CD19-specific CAR sequences to the T cell receptor a constant (TRAC) locus reportedly reduced T cell exhaustion and enhanced CAR-T cell therapeutic potency in a NOD scid gamma (NSG) mouse model of acute lymphoblastic leukemia. 57 In addition, CRISPR-Cas9-transfected human TCR-T cells showed anti-tumor reactivity both in melanoma cell lines and in NSG mouse models of human melanoma. 58 Therapeutic T cells engineered through endogenous TCR modification with CRISPR-Cas9 and exogenous TCR gene transfer were more sensitive to hematological malignancies in vitro than standard TCR-transduced T cells. 59 Extensive applications of CAR-T cell therapy in various tumors is deterred because existing CARs are unspecific and do not strictly recognize cancer antigens over normal tissues. 60 Fortunately, CRISPR technology can be employed to identify novel CARs that can potentially address this issue. Pooled high-throughput CRISPR screening of tumor models can help identify novel therapeutic targets for immunotherapy, such as PTPN2 in melanoma mouse models. 61, 62 Moreover, CRISPR-Cas9 technology has been used to develop CD33 knockout hematopoietic stem cells that allowed anti-CD33 CAR-T cells to specifically eliminate acute myeloid leukemia (AML) tumor cells without affecting normal myeloid cells. 60 Another concern in adoptive immunotherapy is the possibility of triggering graft-versus-host disease. Although this problem can be avoided by using autogenous T cells, it is time consuming and costly to produce sufficient therapeutic cells tailored to individual patients. 56 Using CRISPR-Cas9 technology to edit CAR-T cells would help overcome immunological incompatibility and decrease expenses, because the edited non-alloreactive cells are usable in any patients. For example, CRISPR-Cas9 gene editing was reportedly used to generate allogeneic CAR-T cells deficient in TCR and human leukocyte antigen (HLA) class I molecules. The experiments demonstrated that these CAR-T cells showed anti-tumor activity in the mouse model, which was enhanced by the simultaneous knockout of programmed cell death 1 (PDCD1 or PD1). 63 Gene-edited CAR-T cells did not induce graft-versus-host disease, thereby greatly increasing the practicality of allogeneic T cells in immunotherapy.
Successful tumor inhibition involves improvement of CAR and TCR specificity and obliteration of tumor immune escape. Immune-suppressive pathways in tumor microenvironment include PD1/PDL1, CTLA-4/B7-2, and TIM3/Galectin-9. 64, 65 Inhibition of the PD1/ PDL1 pathway using systemic PD1 monoclonal antibodies (e.g., ipilimumab, pembrolizumab, and nivolumab) constitutes a promising cancer treatment approach. 66 However, systemic administration of PD1 inhibitors could cause immune-related side effects. 67 Adoptive T cell immunotherapy using CRISPR-Cas9 to generate PD1-disrupted human primary T cells partially avoided those side effects even as it enhanced cytokine secretion and toxicity against tumor cells both in vitro and in vivo. 63, 68, 69 This promising outcome eventually led to the first clinical trial that investigated the safety and efficacy of CRISPR-Cas9-engineered PD1-knockout T cells in lung cancer patients. 13 Ultimately, the combination of CAR modification, immune checkpoint inhibition, and CRISPR-Cas9 technology is a therapeutic strategy with massive potential for advancements in treating solid tumors. 63, 69 Clinical Trials
This section summarizes the details of all clinical trials with CRISPRCas9 technology regardless of status and disease types (Table 1) In addition, CRISPR screening identified the RIPK1 inhibitor as a potential target for amplifying anti-tumor immune reactivity. A clinical trial examining this effect on pancreatic tumors has been approved that will combine pembrolizumab with RIPK1 inhibitor www.moleculartherapy.org Table 1 are the forthcoming tests of EDIT-101, a CRISPR-based experimental medicine investigated for the treatment of Leber congenital amaurosis type 10 (LCA10) by Editas Medicine, a leading genome-editing company. 70 LCA10 is a monogenic inherited retinal dystrophy disorder caused by aberrant splicing deeply due to bi-allelic loss-of-function intron 26 c.2991+1655A > G mutations in CEP290 gene. 71 Subretinally administrated EDIT-101 works to correct these splicing defects and restore wild-type CEP290 mRNA expression through its specific CRISPR-Cas9 components packaged in AAV5 viral vector. 72 The U.S.
Review
Food and Drug Administration (FDA) has accepted the investigational new drug (IND) approval of the clinical trials of the CRISPR genome-editing therapeutic product EDIT-101, which creates a critical impetus for translation of CRISPR-Cas9 technology. 73 These promising lines of evidence introduce an era wherein CRISPRCas9-mediated gene editing could be used in the clinical setting to precisely modify and control site-specific knockins without uncontrolled genomic damage.
Problems and Challenges in the Clinical Translation of CRISPRCas9 Technology
Despite the increasing maturity of CRISPR-Cas9 technology, its safety and efficiency are important concerns requiring comprehensive studies. Clinical translation of the CRISPR-Cas9 system is impeded by off-target alterations. 74 Specifically, gRNAs tend to have relatively high mismatch tolerance; hence, Cas9 commonly cleaves off-target sites that have sequences similar to those of target genes. 75 Efforts to increase the specificity of CRISPR-Cas9 have improved gRNA design, 76 generated new versions of the Cas9 nuclease, [77] [78] [79] and optimized delivery vehicles. Newly designed xCas9 and HypaCas9 variants are hyper-accurate without reducing target activity for precise genome editing. 79, 80 Partial sequence replacement of gRNA is another strategy to prevent off-target effects without compromising on-target activity. 81 Furthermore, newly reported CRISPR-Cas inhibitors may be harnessed as effective regulators of CRISPR-Cas-mediated gene editing in the future. 82 In addition, GUIDE-seq, BLESS, HTGTS, and Digenome-seq are among the new tools designed to predict Table 1 . Review gene-editing outcomes and identify potential off-target sites. 83, 84 However, off-target alterations are only one form of genotoxicity attributable to CRISPR-Cas9 gene editing. CRISPR-Cas9 could introduce unexpected large deletions and complex rearrangements into edited cells. 85 In mouse and human cell lines, for example, large deletions amounting to 9.5 kb and complex genomic rearrangements (insertions, inversions, and combined forms) have been reported at regions adjacent and distal to targeted cut sites. 86 Typically, CRISPR-Cas9 optimization and off-target tool design use standard human genomes as a reference. However, individual human genetic variations may lead to unexpected off-target gene editing even with well-designed gRNA. 87 Therefore, translational application of CRISPR-Cas9 must be coupled with whole-genome sequence analysis, large-scale off-target predictions, evaluation of individual intensive genotoxicity risk, and close patient monitoring.
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The well-known tumor suppressor p53 is important in CRISPR-Cas9-induced DSB repair. 88 When cells recognize CRISPR-Cas9-induced DNA damage, p53 is activated to trigger cell-cycle arrest and kill transformed cells. Therefore, precise genome engineering in human pluripotent stem cells (hPSCs) with wild-type p53 was less efficient than that in hPSCs with inhibited p53. 89 These findings suggest that successfully transformed cells would be mostly p53 inhibited and may exhibit unknown characteristics that could even increase tumorigenesis potency. Thus, more research is necessary to understand how CRISPR-Cas9 technology affects p53.
The immunogenicity of Cas9 nuclease is another concern that should be considered during clinical translation of CRISPR-Cas9 technology. The serum of some donors naturally contains Cas9 antibodies, with 79% exhibiting anti-saCas9 and 65% exhibiting anti-SpCas9. 90 96% of the donors evaluated (46/48 in the study) showed a preexisting T cell immune memory against SpCas9. 91 Human anti-Cas9 immune response causes low editing efficiency and could lead to a serious immune storm in patients receiving CRISPR-Cas9 treatment.
A final serious concern is the generalizability and efficiency of CRISPR-Cas9 technology. For instance, protospacer adjacent modif (PAM; NGG) sequences are necessary at target sites for accurate CRISPR-Cas9 genome editing. Until recently, existing Cas9 has been recognized in only a few PAM sequences, limiting extensive application of this technology. Fortunately, newly developed xCas9 can recognize a broader range of PAM sequences (NG, GAA, and GAT), quadrupling the scope for the application of CRISPR-Cas9 technology. 79 In addition, precise CRISPR-Cas9-mediated genomic insertions experience low efficiency via HDR; 29 however, this efficiency can be enhanced through suppression of NHEJ, nucleofection delivery and the use of a single-stranded DNA (ssDNA) donor instead of double-stranded DNA (dsDNA). 68, 92, 93 In conclusion, further studies are required to clarify the safety and efficiency of CRISPR-Cas9 before the technology is adaptive to clinical settings.
Conclusions and Future Directions
The rapidly developing suite of CRISPR-Cas9-mediated gene-editing technologies is yielding enormously beneficial results in the modern life sciences. These tools allow for precise genomic modifications, transcriptional regulation, and epigenetic editing with high efficiency, generality, and simplicity. Undoubtedly, CRISPR systems are endowed with the potential to revolutionize the fields of genetics and medicine. The past few years have witnessed the introduction of metadata era with large-scale analyses of genome sequences, However, translational research of CRISPR-Cas9 technology in biomedicine is imperative and should first target advanced tumors and severe hereditary diseases, despite the preceding ethical concerns. As a versatile and convenient nucleic acid manipulation platform, the CRISPR-Cas9 system can be harnessed to study molecular mechanisms in the process of disease genesis and progression and, more (1) genetically engineer the tumor genome to inhibit tumor cell growth and proliferation and induce more necrosis and apoptosis, or to enhance tumor cells' sensitivity to radiotherapy and some chemotherapeutics; (2) genetically engineer immune cells' genome to increase the secretion of toxic cytokines, or to rescue immune cells from functional inhibition; and (2) genetically engineer normal cells, e.g., bone marrow cells, to protect them from the toxic effects of radiotherapy and chemotherapy. As has been illustrated in this review, recent years have witnessed deepening functional dissection and the ever-expanding translation prospect of CRISPR-Cas9 tools, yet translating these into the clinic remains intractable. Safety is one of those factors that hold us back, including uncontrolled off-target effects, potential immunogenicity, and immunological adverse effects. Efficiency is another one, because advanced-tumor patients after multiline therapy have insufficient immunity and anergic even exhausted immune cells.
Altogether, notwithstanding significant advancements and newly emerging challenges for CRISPR-Cas9 technology, major improvements and therapeutic applications can be envisioned.
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